A Study Assessing Oral Immune related Adverse Events Secondary to Programmed Cell Death‐1 inhibitors Treatment in Cancer Patients
Latest Information Update: 27 Apr 2020
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Cancer
- Focus Adverse reactions
Most Recent Events
- 27 Apr 2020 New trial record
- 01 Mar 2020 Results published in the Oral Diseases